A phase II trial of oxaliplatin, capecitabine, irinotecan (XELOXIRI) and bevacizumab as first-line therapy for patients with metastatic colorectal cancer
- Conditions
- metastatic colorectal cancer
- Registration Number
- JPRN-UMIN000039783
- Lead Sponsor
- Sapporo Medical University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 47
Not provided
1. Need to drain malignant fluid. 2. With a history of allergic response to Fluorouracil or Levofolinate calcium or Platinium. 3. Pregnant or lactating women or women of childbearing potential. 4. Uncontrolled infection. 5. Evidence of interstinal lung disease, or pulmonary fibrosis. 6. Clinically significant (i.e. active) cardiovascular disease or past or current history (within the last 1 year) of myocardial infarction. 7. Uncontrollable ulcer indigestive tract. 8. Radiological evidence of CNS metastases or brain cancer. 9. Complication of cerebrovascular disease or symptoms within 1 year. 10. Any surgical treatments within 4 weeks. 11. Administering antithrombotic drug within 10 days. Need to administrate or having anti-platelets therapy 12. Multiple primary cancers within 5 years. 13. Other conditions not suitable for this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival
- Secondary Outcome Measures
Name Time Method Overall survival, response rate, safety, R0 resection rate, efficacy by the RAS mutation status, QO